The rebirth of the contact pathway: a new therapeutic target

Area of Science:

• Hematology
• Pharmacology
• Thrombosis Research

Background:

• Current anticoagulants (vitamin-K antagonists, DOACs) carry significant bleeding risks.
• Developing safer antithrombotic drugs with minimal impact on hemostasis is a major research focus.
• Plasma contact proteins factor XI (FXI) and factor XII (FXII) are implicated in thrombosis but not essential for hemostasis.

Purpose of the Study:

• To review preclinical and clinical evidence supporting the role of the contact system in thromboembolic disease.
• To discuss the potential of targeting FXI and FXII for novel antithrombotic therapies.

Main Methods:

• Review of preclinical studies on FXI and FXII inhibitors.
• Analysis of phase 2 clinical trial data for FXI/FXIa inhibitors in venous thrombosis prophylaxis.
• Discussion of emerging research on FXII inhibitors.

Main Results:

• Compounds targeting FXI/FXIa demonstrate antithrombotic efficacy comparable to standard care in knee replacement patients.
• FXII inhibitors show potential for preventing thrombosis related to medical devices.
• Preclinical and early clinical data support the hypothesis that FXI and FXII contribute to thromboembolic events.

Conclusions:

• Inhibitors of contact activation, especially FXI inhibitors, are promising for preventing thromboembolic disease.
• Larger clinical trials are necessary to confirm efficacy and bleeding safety profiles.
• Targeting the contact system offers a potential alternative to current anticoagulation strategies.